GSK.L - GlaxoSmithKline plc

LSE - LSE Delayed price. Currency in GBp
1,488.20
-2.20 (-0.15%)
At close: 4:36PM BST
Stock chart is not supported by your current browser
Previous close1,490.40
Open1,487.00
Bid1,454.00 x 175400
Ask1,495.00 x 417900
Day's range1,481.60 - 1,508.60
52-week range1,236.40 - 1,724.50
Volume8,846,890
Avg. volume9,501,768
Market cap73.114B
Beta1.03
PE ratio (TTM)48.01
EPS (TTM)31.00
Earnings date25 Jul 2018
Forward dividend & yield0.80 (5.66%)
Ex-dividend date2018-05-10
1y target est1,540.22
  • Regulators flag possible birth defect link to GSK's HIV drug
    Reuters2 days ago

    Regulators flag possible birth defect link to GSK's HIV drug

    U.S. and European regulators said they were assessing evidence that GlaxoSmithKline's (GSK.L) HIV drug dolutegravir might be linked to serious birth defects, casting a shadow over a medicine that has been a key profit driver in recent years. Friday's move by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) follows preliminary data from a study in Botswana which found four cases of neural tube defects in babies born to mothers who became pregnant while taking the drug.

  • Reuters - UK Focus2 days ago

    Regulators flag possible birth defect link to GSK's HIV drug

    U.S. and European regulators said they were assessing evidence that GlaxoSmithKline (Other OTC: GLAXF - news) 's HIV drug dolutegravir might be linked to serious birth defects, casting a shadow over a medicine that has been a key profit driver in recent years. Friday's move by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) follows preliminary data from a study in Botswana which found four cases of neural tube defects in babies born to mothers who became pregnant while taking the drug.

  • Reuters - UK Focus2 days ago

    Hikma reaffirms full-year revenue forecast, cites better generics business

    Hikma Pharmaceuticals Plc (Frankfurt: A0HG69 - news) on Friday reaffirmed its revenue guidance for the full year, noting its generics business was performing better due to a favourable product mix, despite continued pricing pressure in the United (Shenzhen: 000925.SZ - news) States. The drugmaker, which was forced to cut revenue guidance for its generics business three times in 2017, said it continued to expect revenue from the business to be between $550 million and $600 million in 2018. Sigurdur Olafsson, former generics chief at drug giant Teva Pharmaceuticals, was named Hikma's chief executive officer in February.

  • GSK bets on lift from new lung drugs ahead of Advair's last gasp
    Reuters3 days ago

    GSK bets on lift from new lung drugs ahead of Advair's last gasp

    GlaxoSmithKline (GSK.L) is putting more marketing muscle behind its new lung drugs and is looking for a sales boost as top respiratory experts gather to analyse clinical trials data at a meeting in San Diego this weekend. The British drugmaker has dominated the lung drug market for decades, but its pre-eminence is no longer guaranteed, given declining sales of the ageing Advair inhaler, which could soon face generic competition in the United States. The market is also seeing intensified pricing pressure, raising doubts over the long-term profitability of newer drugs.

  • Reuters - UK Focus3 days ago

    GSK bets on lift from new lung drugs ahead of Advair's last gasp

    GlaxoSmithKline (Other OTC: GLAXF - news) is putting more marketing muscle behind its new lung drugs and is looking for a sales boost as top respiratory experts gather to analyse clinical trials data at a meeting in San Diego this weekend. The British drugmaker has dominated the lung drug market for decades, but its pre-eminence is no longer guaranteed, given declining sales of the ageing Advair inhaler, which could soon face generic competition in the United States. The market is also seeing intensified pricing pressure, raising doubts over the long-term profitability of newer drugs.

  • Glaxo Cuts Jobs in Finance, Adds Ones in Cancer in Hunt for Drugs
    Bloomberg3 days ago

    Glaxo Cuts Jobs in Finance, Adds Ones in Cancer in Hunt for Drugs

    GlaxoSmithKline Plc is cutting finance and accounting positions while bringing in people with cancer and science backgrounds as the U.K.’s biggest drug company shifts spending to develop its best new treatments. The new strategy has led to a “reasonable number” of job cuts, said Luke Miels, president of the London-based company’s global pharmaceutical division, declining to quantify them. Glaxo at the same time is increasing the number of medical science liaisons, specialists who establish relationships with top doctors, as well other roles, he said in an interview.

  • Takeda CEO prescribes surgical R&D cuts after $62 billion Shire deal
    Reuters3 days ago

    Takeda CEO prescribes surgical R&D cuts after $62 billion Shire deal

    For Christophe Weber, the boss of Japan's Takeda Pharmaceutical , securing a $62 billion (46 billion pound) deal last week to buy drugmaker Shire (SHP.L) at the fifth time of asking was the easy bit. At the same time he must win shareholders' support for the largest-ever overseas purchase by a Japanese company - something he told Reuters could be helped by bringing in one or more long-term, large strategic investor.

  • Reuters - UK Focus3 days ago

    FOCUS-Takeda CEO prescribes surgical R&D cuts after $62 bln Shire deal

    For Christophe Weber, the boss of Japan's Takeda Pharmaceutical, securing a $62 billion deal last week to buy drugmaker Shire (Xetra: S7E.DE - news) at the fifth time of asking was the easy bit. At the same time he must win shareholders' support for the largest-ever overseas purchase by a Japanese company - something he told Reuters could be helped by bringing in one or more long-term, large strategic investor. When you combine two pipelines you can be more stringent," he said in London, where he is meeting investors and analysts.

  • MPs call for post-Brexit pharmaceutical deal with EU
    Reuters4 days ago

    MPs call for post-Brexit pharmaceutical deal with EU

    Britain must make a continued form of membership of the European Medicines Agency (EMA) a priority to protect the pharmaceutical industry and patients after Brexit, MPs said. The highly regulated industry fears disruption as the EMA relocates from London to Amsterdam, creating uncertainty about drug approvals after 2019. The EMA is already reallocating regulatory work done by experts in Britain to other countries.

  • Reuters - UK Focus4 days ago

    UK lawmakers call for post-Brexit pharmaceutical deal with EU

    Britain must make a continued form of membership of the European Medicines Agency (EMA) a priority to protect the pharmaceutical industry and patients after Brexit, UK lawmakers said. The highly regulated industry fears disruption as the EMA relocates from London to Amsterdam, creating uncertainty about drug approvals after 2019. The EMA is already reallocating regulatory work done by experts in Britain to other countries.

  • AstraZeneca's (AZN) Asthma Drug Fasenra Fails in COPD Study
    Zacks6 days ago

    AstraZeneca's (AZN) Asthma Drug Fasenra Fails in COPD Study

    AstraZeneca's (AZN) asthma drug Fasenra (benralizumab) fails to meet the primary endpoint in a late-stage study evaluating it for a new indication - COPD.

  • Reuters11 days ago

    Drugmaker GSK rings in more change as CFO heads for exit in 2019

    GlaxoSmithKline Plc, Britain's biggest drugmaker, faces more top management change with Chief Financial Officer Simon Dingemans set to retire next year. The former Goldman Sachs investment banker, who joined in 2011, will step down from the board in May 2019, the company said on Wednesday. Dingemans' departure provides a further opportunity for Chief Executive Emma Walmsley to stamp her imprint on the group as she tries to boost sales and improve productivity in the core pharmaceuticals division.

  • Reuters - UK Focus11 days ago

    Drugmaker GSK rings in more change as CFO heads for exit in 2019

    GlaxoSmithKline Plc (Other OTC: GLAXF - news) , Britain's biggest drugmaker, faces more top management change with Chief Financial Officer Simon Dingemans set to retire next year. The former Goldman Sachs (NYSE: GS-PB - news) investment banker, who joined in 2011, will step down from the board in May 2019, the company said on Wednesday. Dingemans' departure provides a further opportunity for Chief Executive Emma Walmsley to stamp her imprint on the group as she tries to boost sales and improve productivity in the core pharmaceuticals division.

  • Reuters11 days ago

    Drugmaker GSK rings in more change as CFO heads for exit in 2019

    GlaxoSmithKline Plc (GSK.L), Britain's biggest drugmaker, faces more top management change with Chief Financial Officer Simon Dingemans set to retire next year. The former Goldman Sachs (GS.N) investment banker, who joined in 2011, will step down from the board in May 2019, the company said on Wednesday. Dingemans' departure provides a further opportunity for Chief Executive Emma Walmsley to stamp her imprint on the group as she tries to boost sales and improve productivity in the core pharmaceuticals division.

  • Reuters - UK Focus11 days ago

    GlaxoSmithKline CFO Dingemans to retire in 2019

    GlaxoSmithKline Plc chief financial officer Simon Dingemans has decided to retire, the company said on Wednesday. Dingemans will step down from the board in May 2019, the company said in a statement. The ...

  • Forbes14 days ago

    Follow These Dividend Leaders For 5% To 12% Yields Plus Upside

    From utilities to REITs (real estate investment trusts) to high yield bonds, many are getting crushed as rates rise. All pay 5% to 12% dividends and have additional price upside to boot. GlaxoSmithKline is a U.K.-based pharmaceutical stock that has earned a place among healthcare’s blue-chip elite.

  • Emergent (EBS) Misses on Q1 Earnings, Retains 2018 View
    Zacks16 days ago

    Emergent (EBS) Misses on Q1 Earnings, Retains 2018 View

    Emergent's (EBS) earnings and revenues lag estimates in Q1. However, the top line improves marginally year over year, driven by higher contract manufacturing revenues.

  • Bloomberg16 days ago

    Glaxo's Advair Is the $100 Billion Asthma Drug That Won't Die

    Sharon Bassett tries to stretch a month’s supply of GlaxoSmithKline Plc’s Advair over 60 days to save money on the asthma treatment because the U.S. lacks a cheaper generic version. Since 2001, Advair has helped children and adults with chronic lung diseases while raking in about $100 billion in sales for Glaxo along the way. “It’s been a particularly long and frustrating journey,” said Steve Miller, chief medical officer of Express Scripts Holding Co., which negotiates drug prices for employers and insurers.

  • Cash conundrum has investors clamouring for capital ideas
    Reuters17 days ago

    Cash conundrum has investors clamouring for capital ideas

    Splashing corporate cash may be in vogue, with bumper share buybacks and record takeovers, but some investors are demanding firms spend more on improving assets they already own. Of nearly a dozen fund managers contacted by Reuters, three-quarters expressed concern about the way companies are allocating capital during a period of relatively healthy cashflow. "If you are in boom times, by and large capital tends to be allocated poorly," Ben Whitmore, manager of the Jupiter Special Situations Fund, said.

  • Reuters - UK Focus18 days ago

    Too many cancer drugs? Crowded market gives investors pause

    In London's world-famous Great Ormond Street children's hospital, Dr. Karin Straathof is excited about a new cell-based medicine that offers hope for toddlers with incurable nerve tissue cancer. The new therapy using engineered white blood cells has shown anti-tumour activity in the hardest to treat neuroblastoma patients. "The beauty is that it is very specific in targeting the cancer cells, while leaving healthy tissue unharmed," Straathof told Reuters, after presenting her early findings at a science meeting in Chicago in April.

  • U.K. Deal Bonanza Poised to Hit Record Amid Brexit Concerns
    Bloomberg20 days ago

    U.K. Deal Bonanza Poised to Hit Record Amid Brexit Concerns

    Dealmaking in the U.K. is poised to hit a record this year as a surge in foreign takeover interest eclipses Brexit jitters. Acquisitions involving British firms have soared to more than $275 billion this year, on track for an annual high, according to data compiled by Bloomberg, helping power an acceleration in global deals. Takeda Pharmaceutical Co. is pursuing U.K.-listed biotech Shire Plc for $64 billion and Britain’s largest pay-TV company Sky Plc is juggling multiple suitors in the two biggest deals through April.

  • Bloomberg20 days ago

    Deals Bonanza in U.K. Poised to Hit a Record Amid Brexit Fears

    Dealmaking by U.K. companies such as J Sainsbury Plc, GlaxoSmithKline Plc and Sky Plc is poised to hit a record this year amid a surge in both foreign takeover interest and domestic consolidation efforts ...

  • Glaxo (GSK) Q1 Earnings Lag, Shingrix Vaccines Sales Solid
    Zacks24 days ago

    Glaxo (GSK) Q1 Earnings Lag, Shingrix Vaccines Sales Solid

    Glaxo's (GSK) Q1 earnings fall short of estimates while revenues rise year over year. The company's vaccine segment performs strongly on the back of Shingrix sales.

  • Glaxo's Shingles Vaccine 'Encouraging' But Shares Dip On Quarterly Lag
    Investor's Business Daily25 days ago

    Glaxo's Shingles Vaccine 'Encouraging' But Shares Dip On Quarterly Lag

    Shingrix sales were strong in the first quarter, GlaxoSmithKline said, though shares dipped on the company's broader revenue and profit lag.

  • Associated Press25 days ago

    Stronger pound weighs on revenues at drugmaker GSK

    LONDON (AP) — Pharmaceutical and consumer goods maker GlaxoSmithKline says first-quarter revenue dropped 2 percent as a stronger pound offset encouraging sales of a new shingles treatment.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes